Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, discusses the simultaneous inhibition of MCL-1 and BCL-2 with the combination with S63845 and venetoclax for the treatment of myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).